靶向 GPRC5D 的免疫治疗在复发/难治性多发性骨髓瘤中的最新进展:2022 ASH 年会更新
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
62.9分
★★★☆☆
站内排序·非疗效
FRONTIER PAPERS
Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting.
Novel Approaches of Cellular Therapy in Multiple Myeloma: Focus on Chimeric Antigen Receptor T-Cells.
CAR-T 细胞疗法在多发性骨髓瘤治疗中显示出显著获益。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。